Multiplex Assay Kit for Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay)

phosphatidylcholine-sterol O-acyltransferase; Phospholipid-cholesterol acyltransferase

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 80-103 94
EDTA plasma(n=5) 78-97 82
heparin plasma(n=5) 87-94 91
sodium citrate plasma(n=5) 78-95 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 85-97% 78-89% 94-101% 96-103%
EDTA plasma(n=5) 79-103% 88-95% 97-105% 88-96%
heparin plasma(n=5) 91-99% 78-92% 78-94% 94-101%
sodium citrate plasma(n=5) 80-99% 96-103% 99-105% 98-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:LCAT) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Int J Rheum Dis Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgia PubMed: 26585319
Inflammation. Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice withExperimental Sepsis. pubmed:28028754
British journal of cancer A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. pubmed:28664912
Journal of Agricultural and Food Chemistry Lipid-lowering effects of medium-chain triglyceride-enriched coconut oil in combination with licorice extracts in experimental hyperlipidemic mice Pubmed: 30244576
Experimental and Therapeutic Medicine Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D‑LC‑MS/MS Doi: 10.3892/etm.2018.6818
British Journal of Cancer Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. Pubmed: 31388184
BIOMEDICINE & PHARMACOTHERAPY The synergistic mechanism of total saponins and flavonoids in Notoginseng− Safflower pair against myocardial ischemia uncovered by an integrated … Pubmed: 32739736
Biomedicine & Pharmacotherapy Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction?¡­
Cell Metab Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression Pubmed:35235775
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPJ516Hu01 Recombinant Lecithin Cholesterol Acyltransferase (LCAT) Positive Control; Immunogen; SDS-PAGE; WB.
RPJ516Hu02 Recombinant Lecithin Cholesterol Acyltransferase (LCAT) Positive Control; Immunogen; SDS-PAGE; WB.
PAJ516Hu01 Polyclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
PAJ516Hu02 Polyclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
LAJ516Hu71 Biotin-Linked Polyclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC.
MAJ516Hu21 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB,IHC
MAJ516Hu25 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
MAJ516Hu27 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
MAJ516Hu29 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
MAJ516Hu24 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
MAJ516Hu26 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
MAJ516Hu28 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
MAJ516Hu22 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB,IHC
MAJ516Hu23 Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT) WB; IHC; ICC; IP.
SEJ516Hu ELISA Kit for Lecithin Cholesterol Acyltransferase (LCAT) Enzyme-linked immunosorbent assay for Antigen Detection.
SCJ516Hu CLIA Kit for Lecithin Cholesterol Acyltransferase (LCAT) Chemiluminescent immunoassay for Antigen Detection.
LMJ516Hu Multiplex Assay Kit for Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.